Medical Radiology and Radiation Safety. 2021. Vol. 66. № 5. P. 95–100
Estimation of Radiotherapy Efficiency of Head-and-Neck Cancer Based on Tumor Control Probability Model
Е.S. Sukhikh1,2, L.G. Sukhikh 2, Ya.N. Sutygina1,2, P.V. Izhevsky3, I.N. Sheino3, O.M.Stakhova2,4, M.I. Klinovitskaya2
1Tomsk Regional Oncology Center, Tomsk, Russia
2National Research Tomsk Polytechnic University, Tomsk, Russia
3 A.I. Burnasyan Federal Medical Biophysical Center, Moscow, Russia
4Multidisciplinary Clinical Medical Ccenter “Medical city”, Tyumen, Russia
Contact person: Olga Mikhailovna Stakhova: Этот адрес электронной почты защищен от спам-ботов. У вас должен быть включен JavaScript для просмотра. .
ABSTRACT
Purpose: Evaluation of the expected effectiveness of radiation therapy based on models of the local tumor control probability (Tumor Control Probability – TCP) for the head-neck cancer.
Material and мethods: The study used data from 11 patients with locally advanced head-neck cancer (larynx, oropharynx, and oral cavity). For each patient two dosimetric treatment plans have been prepared: SIB-VMAT (70 Gy per tumor, 50 Gy per lymph nodes, 25 fractions) and SEQ-VMAT (70 Gy per tumor, 50 Gy per lymph nodes, 35 fractions). The developed plans were analyzed using A. Niemierko's TCP model with parameters obtained by B. Maciejewski (TCD50 = 70.26 Gy with a 49-day total treatment time), taking into account the dose–volume histograms and the total treatment time.
Results: The developed plans ensured a high level of coverage (98–98 %) of the Clinical treatment volume (CTV) in all but one patient. The average TCP SIB-VMAT is 99.9 % due to the very short total treatment time. The average TCP for SEQ-VMAT is 61.0%. For one patient, both SIB-VMAT and SEQ-VMAT showed zero expected efficacy due to 95–95 % CTV coverage.
Conclusion: The use of TCP model allows analyzing personalized treatment plans for patients and developing adaptive treatment regimens with an increase in the total dose, dose per fraction, and a decrease in the total treatment time.
Key words: locally advanced cancer head and neck, volumetric modulated arc therapy, simultaneous integrated dose escalation, tumor control probability, TCP model
For citation: Sukhikh ЕS, Sukhikh LG, Sutygina YaN, Izhevsky PV, Sheino IN, Stakhova OM, Klinovitskaya MI. Estimation of Radiotherapy Efficiency of Head-and-Neck Cancer Based on Tumor Control Probability Model. Medical Radiology and Radiation Safety 2021;66(5):95-100.
DOI: 10.12737/1024-6177-2021-66-5-95-100
References
1. Каприн А.Д, Старинский В.В, Петрова Г.В. Злокачественные новообразования в России в 2017 году. Заболеваемость и смертность. 2018. Available from: http://www.oncology.ru/service/statistics/malignant_tumors/2017.pdf.
2. Beitler JJ, Zhang Q, Fu KK, Trotti A, Spencer SA, Jones CU, et al. Final Results of Local-Regional Control and Late Toxicity of RTOG 9003: A Randomized Trial of Altered Fractionation Radiation for Locally Advanced Head and Neck Cancer // International Journal of Radiation Oncology Biology Physics. 2014. V.89, No. 1. P. 13–20. DOI: 10.1016/j.ijrobp.2013.12.027. PMID: 24613816.
3. Dragan T., Beauvois S, Moreau M, Paesmans M, Vandekerkhove C, Cordier L, et al. Clinical Outcome and Toxicity after Simultaneous Integrated Boost IMRT in Head and Neck Squamous Cell Cancer Patients // Oral Oncology. 2019. No. 98. P. 132–140. DOI: 10.1016/j.oraloncology.2019.09.012. DOI: 10.1016/j.oraloncology.2019.09.012. PMID: 31586895.
4. Maciejewski B, Withers HR, Taylor JMG, Hliniak A. Dose Fractionation and Regeneration in Radiotherapy for Cancer of the Oral Cavity and Oropharynx: Tumor Dose-Response and Repopulation // International Journal of Radiation Oncology, Biology, Physics. 1989. V.16, No. 3. P. 831–843. DOI: 10.1016/0360-3016(89)90503-8. PMID: 2921175.
5. Orlandi E, Palazzi M, Pignoli E, Fallai C, Giostra A, Olmi P. Radiobiological Basis and Clinical Results of the Simultaneous Integrated Boost (SIB) in Intensity Modulated Radiotherapy (IMRT) for Head and Neck Cancer: A Review // Critical Reviews in Oncology/Hematology. 2010. V.73, No. 2. P. 111–125. DOI: 10.1016/j.critrevonc.2009.03.003. PMID: 19409808.
6. Chao KSC, Ozyigit G, Tran BN, Cengiz M, Dempsey JF, Low DA. Patterns of Failure in Patients Receiving Definitive and Postoperative IMRT for Head-and-Neck Cancer // International Journal of Radiation Oncology Biology Physics. 2003. V.55, No. 2. P. 312–321. DOI: 10.1016/s0360 -3016(02)03940-8. PMID: 12527043.
7. Spiotto MT, Weichselbaum RR Comparison of 3D Confromal Radiotherapy and Intensity Modulated Radiotherapy with or Without Simultaneous Integrated Boost During Concurrent Chemoradiation for Locally Advanced Head and Neck Cancers // PLoS ONE. 2014. V.9, No. 4. DOI: 10.1371/journal.pone.0094456. PMID: 24714187.
8. Vlacich G, Stavas MJ, Pendyala P, Chen SC, Shyr Y, Cmelak AJ. A Comparative Analysis Between Sequential Boost and Integrated Boost Intensity-Modulated Radiation Therapy with Concurrent Chemotherapy for Locally-Advanced Head and Neck Cancer // Radiation Oncology. 2017. V.12, No. 1. DOI: 10.1186/s13014-016-0756-x. PMID: 28086954.
9. Vanasek J, Odrazka K, Dusek L, Jarkovsky J, Michalek R, Chrobok V, et al. Experience with Intensity-Modulated Radiotherapy in the Treatment of Head and Neck Cancer // Journal of BUON. 2013. V.18, No. 4. P. 970–976. PMID: 24344025.
10. Farrag A, Voordeckers M, Tournel K, De Coninck P, Storme G. Pattern of Failure after Helical Tomotherapy in Head and Neck Cancer // Strahlentherapie und Onkologie. 2010. V.186, No. 9. P. 511–516. DOI: 10.1007/s00066-010-2130-5. PMID: 20803182.
11. Barry MA, Hussein M, Schettino G. Evaluating the Propagation of Uncertainties in Biologically Based Treatment Planning Parameters // Front. Oncol. 2020. DOI: 10.3389/fonc.2020.01058. PMID: 32793468.
12. Niemierko A. Reporting and Analyzing Dose Distributions: A Concept of Equivalent Uniform Dose // Medical Physics. 1997. V.24, No. 1. P. 103–110. DOI: 10.1118/1.598063. PMID: 9029544.
13. Gay HA., Niemierko A A. Free Program for Calculating EUD-Based NTCP and TCP in External Beam Radiotherapy // Physica Medica. 2007. No. 3-4. P. 115–125. DOI: 10.1016/j.ejmp.2007.07.001. PMID: 17825595.
14. Bigelow EO, Seiwert TY, Fakhry C. Deintensification of Treatment for Human Papillomavirus-Related Oropharyngeal Cancer: Current State and Future Directions // Oral Oncology. 2020. No. 105. DOI: 10.1016/j.oraloncology.2020.104652. PMID: 32247987.
15. Fakhry C, Zhang Q, Gillison ML, Nguyen-Tân PF, Rosenthal DI, Weber RS, et al. Validation of NRG Oncology/RTOG-0129 Risk Groups for HPV-Positive and HPV-Negative Oropharyngeal Squamous Cell Cancer: Implications for Risk-Based Therapeutic Intensity Trials // Cancer. 2019. V.125, No. 12. P. 2027–2038. DOI: 10.1002/cncr.32025. PMID: 30913305.
16. Overgaard J, Hansen HS, Specht L, Overgaard M, Grau C, Andersen E, et al. Five Compared with Six Fractions Per Week of Conventional Radiotherapy of Squamous-Cell Carcinoma of Head and Neck: DAHANCA 6&7 Randomised Controlled Trial // Lancet. 2003. V.362, No. 9388. P. 933–940. DOI: 10.1016/s0140-6736(03)14361-9. PMID: 14511925.
PDF (RUS) Full-text article (in Russian)
Conflict of interest. The authors declare no conflict of interest.
Financing. The study had no sponsorship.
Contribution. Article was prepared with equal participation of the authors.
Article received: 23.12.2020.
Accepted for publication: 20.01.2021.